After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.
After Affymetrix's shareholders approved the acquisition, Thermo Fisher was able to close the deal for a total purchase price of $1.3 billion.
Initially studying pancreatic tissue, the team also linked their findings to methylation patterns in blood, suggesting the possibility of developing a non-invasive test.
The company attributed increases to both its revenues and expenses to the 2014 acquisition of RedPath Integrated Pathology and two tests from Asuragen.
The researchers will use a new humanized mouse model to obtain genetic information at different life stages of the parasite.
A year after its official launch, the Open Humans project is ready to grow and engage more research teams who want to access its data.
Through a meta-analysis, a consortium linked maternal smoking during pregnancy to differential methylation sites in infant genomes.
The new genome assembly for a western lowland gorilla named Susie has fewer gaps than a prior assembly produced from short reads and Sanger sequencing.
The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
Researchers have linked human lifespan to two genetic variants located near Alzheimer's disease- and lung cancer-associated genes.
The results suggest PAM sites for all kinds of CRISPR systems are more complex than previously thought, even for well-studied systems like S. pyogenes.
Researchers identified a common variant in a long non-coding RNA that may contribute to inflammation seen in patients diagnosed with celiac disease.
OmniSeq has appointed Mark Gardner as its CEO and as a member of its board of directors. Gardner is currently vice president and general manager for Thermo Fisher Scientific's next generation clinical sequencing business. He will transition to his new role at OmniSeq in April. Prior to his work at Thermo Fisher, Gardner held senior management positions at McKinsey, GE Medical Systems, Invitrogen, and Life Technologies.
Lasergen has appointed Timothy Burcham as its CTO. He will help develop the firm's sequencing platform. Burcham has been a member of the firm's scientific advisory board since 2015, and previously spent time developing and launching sequencing systems at Applied Biosystems. The firm also plans to rearrange its board to accommodate three seats from Agilent and will add Steven Arnold, a management consultant who also serves on the board at Houston Methodist Research Institute and Texas Children's Hospital Cancer Center.
The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.